Intravitreal bevacizumab in the management of posttraumatic choroidal neovascular membrane

To report the therapeutic response in the treatment of juxtafoveal choroidal neovascular membrane (CNVM) secondary to traumatic choroidal rupture with intravitreal bevacizumab.

A 20-year-old man presented with distortion of central vision following blunt trauma and was found to have juxtafoveal, classic CNVM associated with a choroidal rupture. The patient underwent intravitreal bevacizumab (1.25 mg/0.05 mL) and was periodically followed up.

Four weeks post injection, best-corrected visual acuity improved to 20/20. Optical coherence tomography revealed regression of CNVM and resolution of subretinal fluid. The anatomic and functional status of the treated eye was maintained at 6 months follow-up. No treatment-related ocular or systemic adverse effects were noted.

Bevacizumab appears to be safe and effective in the treatment of CNVM secondary to choroidal rupture.